UY35157A - Nueva composición farmacéutica conteniendo dimetilsulfóxido - Google Patents

Nueva composición farmacéutica conteniendo dimetilsulfóxido

Info

Publication number
UY35157A
UY35157A UY0001035157A UY35157A UY35157A UY 35157 A UY35157 A UY 35157A UY 0001035157 A UY0001035157 A UY 0001035157A UY 35157 A UY35157 A UY 35157A UY 35157 A UY35157 A UY 35157A
Authority
UY
Uruguay
Prior art keywords
new pharmaceutical
pharmaceutical composition
composition containing
dimethylsulphoxide
containing dimethylsulphoxide
Prior art date
Application number
UY0001035157A
Other languages
English (en)
Inventor
Henriquez Francisco
Campbell Gossett
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35157(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of UY35157A publication Critical patent/UY35157A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Se describen nuevas formulaciones farmacéuticas que contienen dimetilsulfóxido de N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil}acetamida solvato, métodos para utilizar las composiciones en terapia y procedimientos para preparar las mismas.
UY0001035157A 2012-11-30 2013-11-28 Nueva composición farmacéutica conteniendo dimetilsulfóxido UY35157A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261731597P 2012-11-30 2012-11-30

Publications (1)

Publication Number Publication Date
UY35157A true UY35157A (es) 2014-06-30

Family

ID=50828398

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035157A UY35157A (es) 2012-11-30 2013-11-28 Nueva composición farmacéutica conteniendo dimetilsulfóxido

Country Status (29)

Country Link
US (2) US20150328320A1 (es)
EP (2) EP3400933A1 (es)
JP (1) JP6232443B2 (es)
KR (1) KR102206432B1 (es)
CN (2) CN107970214A (es)
AR (1) AR093648A1 (es)
AU (1) AU2013352369B2 (es)
BR (1) BR112015012111A8 (es)
CA (1) CA2891346A1 (es)
CL (1) CL2015001459A1 (es)
EA (2) EA028246B1 (es)
ES (1) ES2686730T3 (es)
HK (1) HK1209047A1 (es)
IL (3) IL300664A (es)
IN (1) IN2015DN04094A (es)
MA (1) MA38121A1 (es)
MX (1) MX2015006867A (es)
MY (1) MY170427A (es)
NZ (1) NZ628395A (es)
PE (1) PE20151024A1 (es)
PH (1) PH12015501168A1 (es)
PL (1) PL2925299T3 (es)
PT (1) PT2925299T (es)
SG (1) SG11201503688SA (es)
TN (1) TN2015000198A1 (es)
TW (2) TW201434468A (es)
UY (1) UY35157A (es)
WO (1) WO2014085371A1 (es)
ZA (1) ZA201503346B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20200178569A1 (en) * 2016-04-29 2020-06-11 Alvin Kershman Method of Coating an Edible Thermoplastic Pet Chew
US10709699B2 (en) 2016-11-25 2020-07-14 Jiangsu Hengrui Medicine Co., Ltd. Pyridone derivative pharmaceutical composition and preparation method thereof
KR102230721B1 (ko) * 2019-02-01 2021-03-22 주식회사 오스코텍 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법
WO2021081554A1 (en) * 2019-10-22 2021-04-29 Chemistryrx Methods for treating congenital epidermal hyperplasia
WO2023219465A1 (ko) * 2022-05-12 2023-11-16 주식회사 지뉴브 안정한 액상 제약 제제

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CN101912400B (zh) * 2004-06-11 2013-06-26 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
DK1819353T3 (da) * 2004-12-07 2011-05-16 Proteolix Inc Sammensætning til proteasomhæmning
CN1872055A (zh) * 2005-06-01 2006-12-06 李�杰 适合儿童应用的阿莫西林与盐酸氨溴索的复方制剂及其处方和制备方法
DK2581078T3 (en) * 2005-10-26 2015-03-02 Cydex Pharmaceuticals Inc Sulfoalkylætercyclodekstrinsammensætninger and processes for the preparation thereof
NZ579098A (en) * 2007-01-16 2012-07-27 Bipar Sciences Inc Formulations for cancer treatment
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN101352419B (zh) * 2007-07-26 2010-08-11 天津药物研究院 一种醋溴茶碱无糖型颗粒剂及其制备方法
KR101478779B1 (ko) * 2007-11-22 2015-01-05 에스케이케미칼주식회사 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
DK3560498T3 (da) * 2009-10-16 2022-11-14 Novartis Ag Kombination, der omfatter en mek-hæmmer og en b-raf-hæmmer
CA2817287A1 (en) 2010-11-11 2012-05-18 Bayer Intellectual Property Gmbh Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
AU2012223639B2 (en) 2011-02-28 2015-03-19 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
CN103596957B (zh) * 2011-04-07 2016-12-07 拜耳知识产权有限责任公司 作为akt激酶抑制剂的咪唑并哒嗪
CN102600132B (zh) * 2012-03-13 2014-05-14 齐鲁制药有限公司 一种含氨磺必利的口服制剂
CN102626394A (zh) * 2012-03-15 2012-08-08 合肥科大生物技术有限公司 一种精氨酸布洛芬颗粒剂及其制备方法

Also Published As

Publication number Publication date
IN2015DN04094A (es) 2015-10-09
JP2016501874A (ja) 2016-01-21
MA38121A1 (fr) 2016-10-31
EP2925299A4 (en) 2016-06-29
TW201434468A (zh) 2014-09-16
EP2925299B1 (en) 2018-06-06
IL238971B (en) 2019-05-30
IL300664A (en) 2023-04-01
ES2686730T3 (es) 2018-10-19
CL2015001459A1 (es) 2015-12-18
PT2925299T (pt) 2018-10-16
PL2925299T3 (pl) 2018-11-30
US20170189408A1 (en) 2017-07-06
EA028246B1 (ru) 2017-10-31
TN2015000198A1 (en) 2016-10-03
PH12015501168A1 (en) 2015-08-10
BR112015012111A2 (pt) 2017-07-11
MY170427A (en) 2019-07-31
CA2891346A1 (en) 2014-06-05
BR112015012111A8 (pt) 2018-01-23
EP2925299A1 (en) 2015-10-07
EP3400933A1 (en) 2018-11-14
ZA201503346B (en) 2016-01-27
AU2013352369B2 (en) 2016-07-28
US20150328320A1 (en) 2015-11-19
NZ628395A (en) 2016-10-28
EA201791411A1 (ru) 2018-03-30
WO2014085371A1 (en) 2014-06-05
EA201591047A1 (ru) 2015-11-30
TW201831187A (zh) 2018-09-01
HK1209047A1 (en) 2016-03-24
IL266415B2 (en) 2024-03-01
SG11201503688SA (en) 2015-06-29
CN107970214A (zh) 2018-05-01
KR20150091352A (ko) 2015-08-10
IL266415B1 (en) 2023-11-01
CN104902876B (zh) 2018-01-19
KR102206432B1 (ko) 2021-01-22
AU2013352369A1 (en) 2015-05-28
CN104902876A (zh) 2015-09-09
AR093648A1 (es) 2015-06-17
IL266415A (en) 2019-06-30
MX2015006867A (es) 2015-10-05
JP6232443B2 (ja) 2017-11-15
PE20151024A1 (es) 2015-07-27
IL238971A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CR20130352A (es) Nueva composición farmaceutica
UY35157A (es) Nueva composición farmacéutica conteniendo dimetilsulfóxido
UY34669A (es) COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
CU20140089A7 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CL2014000821A1 (es) Compuestos derivados de 1h-pirazolo[4,3-c]quinolin-4(5h)-ona, inhibidores de la fosfodiestera 9 (pde9); composicion farmaceutica que los comprende; y agente para mejorar la alteracion cognitiva en la enfermedad de alzheimer.
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
CL2014003232A1 (es) Formulaciones y métodos para la administración vaginal de antiprogestinas.
IN2014KN01664A (es)
GT201500069A (es) Piridinonas bicìclicas novedosas
NI201400080A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
NI201600015A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
ECSP16074478A (es) Compuestos novedosos
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
EP3311809A4 (en) USE OF A PHARMACEUTICAL COMPOSITION IN THE PREPARATION OF A MEDICAMENT FOR PROMOTING CHONDROCYTE PRODUCTION
MX2014008390A (es) Formulaciones de romidepsina y sus usos.
BR112014020008A8 (pt) composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação.
UY34031A (es) Componente de éster aromático en la formulación de composiciones agroquímicas
UY34273A (es) Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparación
CU20130124A7 (es) Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
CO6781490A2 (es) Nueva composición farmacéutica
CO7160058A2 (es) Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis